Volatile Week, but Green? Click to watch the new Podcast.

$0.64 (-2.26%)

Volume: 59.464k

Closed: Jul 01, 2022

Hollow Logo Score: -4.743

Chembio Diagnostics Stock Forecast

$0.64 (-2.26%)

Volume: 59.464k

Closed: Jul 01, 2022

Score Hollow Logo -4.743

Chembio Diagnostics Company Profile

3661 Horseblock Road

Medford NY 11763



Chembio Diagnostics


Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company’s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies. Chembio Diagnostics, Inc. sells its products under STAT-PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; and opTricon to provide DPP Micro Reader, a point-of-care instrument that offers diagnostic results for low analyte concentrations. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE